Skip to content

Released Aug 14, 2019, after the close

10-Q filed Aug 14, 2019, 45 days after period end · 0001390478-19-000045

Q2 2019 · 10-Q
Revenue—
Net Income-$3.13MN/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$6.33N/M vs Q2 2018N/M vs Q1 2019
Operating Cash Flowderived-$4,656,000N/M

What the release said

The release

Same quarter

MetricQ2 2019Q2 2018Q2 2017Q2 2016
Net Income-$3.13M-$6.06M-$5.91M$5.39M
EPS Diluted-$6.33-$1.26-$0.22$0.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR